Relmada Therapeutics (RLMD) Receivables - Other (2016 - 2022)

Relmada Therapeutics (RLMD) has 7 years of Receivables - Other data on file, last reported at $512432.0 in Q4 2022.

• Receivables - Other for Q4 2022 came in at $512432.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $512432.0 (changed N/A YoY), and the FY2022 annual result was $512432.0, changed N/A from the prior year.
• Receivables - Other declined to $512432.0 in Q4 2022 per RLMD's latest filing, from $3.6 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.6 million in Q1 2022 and troughed at $7529.0 in Q1 2020.
• A 5-year average of $418992.1 and a median of $74649.5 in 2019 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2020 and 2022: Receivables - Other tumbled 89.03% in 2020, then soared 4348.55% in 2022.
• A 5-year view of Receivables - Other shows it stood at $67235.0 in 2018, then climbed by 8.71% to $73091.0 in 2019, then rose by 8.71% to $79457.0 in 2020, then surged by 1925.01% to $1.6 million in 2021, then plunged by 68.15% to $512432.0 in 2022.
• Business Quant data shows RLMD's Receivables - Other at $512432.0 in Q4 2022, $3.6 million in Q1 2022, and $1.6 million in Q3 2021.